MEIP - MEIファ―マ (MEI Pharma Inc.) MEIファ―マ

 MEIPのチャート


 MEIPの企業情報

symbol MEIP
会社名 MEI Pharma Inc (MEIファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 MEIファーマ(MEI Pharma Inc.)(旧名:Marshall Edwards Inc)はがんの治療向けの薬物と治療の臨床開発に焦点を当てる癌治療に従事する会社である。同社の臨床薬候補のポートフォリオには、Pracinostat、ME-344及びME-401が含まれる。Pracinostatは、経口で利用可能なヒストンデアセチラーゼ(HDAC)阻害剤であり、急性骨髄性白血病(AML)と骨髄異形成症候群(MDS)などの血液疾患の治療に適応する。ME-344は、イソフラボン系ミトコンドリア阻害剤であり、急速に増殖する細胞中の末端呼吸鎖複合体のミトコンドリア成分を標的とする。ME-401は、血液癌細胞の増殖と生存に重要な役割を果たす分子標的であるホスファチジルイノシトイド3-キナーゼ(PI3K)デルタの経口阻害剤である。Pracinostatは、進行性血液悪性腫瘍と固形腫瘍適応症における複数の第I相と第II相臨床試験で試験される。  MEIファ―マは米国の腫瘍専門の医薬品メ―カ―。がん治療のための新薬の臨床開発に従事。主力製品候補の「Pracinostat」は、骨髄異形成症候群や急性骨髄性白血病などの進行性の血液疾患のために開発されている、経口投与可能なヒストンデアセチラ―ゼ阻害剤である。本社はサンディエゴ。   MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
本社所在地 3611 Valley Centre Drive Suite 500 San Diego CA 92130 USA
代表者氏名 Christine Anna White クリスティーナ・アンナ・ホワイト
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-792-6300
設立年月日 36861
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.meipharma.com
nasdaq_url https://www.nasdaq.com/symbol/meip
adr_tso
EBITDA EBITDA(百万ドル) -28.53300
終値(lastsale) 3.75
時価総額(marketcap) 266574015
時価総額 時価総額(百万ドル) 266.68290
売上高 売上高(百万ドル) 1.62200
企業価値(EV) 企業価値(EV)(百万ドル) 163.93990
当期純利益 当期純利益(百万ドル) -40.06800
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 MEI Pharma Inc revenues decreased 93% to $1.6M. Net loss totaled $40.1M vs. income of $2.7M. Revenues reflect License revenue decrease from $20.9M to $0K Research and development revenue decrease of 32% to $1.6M. Net loss reflects Research and development - Balancing val increase from $6.4M to $15.9M (expense) General and administrative - Balancing v increase of 8% to $7.7M (expense).

 MEIPのテクニカル分析


 MEIPのニュース

   MEIP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MEI Pharma, Inc. and Encourages Investors to Contact the Firm  2020/07/06 15:00:00 PR Newswire
NEW YORK, July 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP). Investors who purchased MEI Pharma securities are encouraged to…
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs  2020/06/02 11:45:45 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aileron Therapeutics Inc (NASDAQ: ALRN ) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cerus Corporation (NASDAQ: CERS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) Emergent Biosolutions Inc (NYSE: EBS ) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) Imara Inc (NASDAQ: IMRA ) Immunovant Inc (NASDAQ: IMVT ) Inari Medical Inc (NASDAQ: NARI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MEI Pharma Inc (NASDAQ: MEIP ) Novo Nordisk A/S (NYSE: NVO ) Protara Therapeutics Inc (NASDAQ: TARA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) Ocugen Inc (NASDAQ: OCGN ) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs.
   MEI Pharma to Present at the Jefferies Virtual Healthcare Conference  2020/05/27 12:00:00 PR Newswire
SAN DIEGO, May 27, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overview and…
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs  2020/06/02 11:45:45 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aileron Therapeutics Inc (NASDAQ: ALRN ) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cerus Corporation (NASDAQ: CERS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) Emergent Biosolutions Inc (NYSE: EBS ) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) Imara Inc (NASDAQ: IMRA ) Immunovant Inc (NASDAQ: IMVT ) Inari Medical Inc (NASDAQ: NARI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MEI Pharma Inc (NASDAQ: MEIP ) Novo Nordisk A/S (NYSE: NVO ) Protara Therapeutics Inc (NASDAQ: TARA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) Ocugen Inc (NASDAQ: OCGN ) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs.
   MEI Pharma to Present at the Jefferies Virtual Healthcare Conference  2020/05/27 12:00:00 PR Newswire
SAN DIEGO, May 27, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overview and…
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry  2020/05/21 12:36:00 Zacks Investment Research
MEI Pharma (MEIP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?  2020/05/15 13:09:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in MEI Pharma, Inc. (MEIP).
   The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs  2020/06/02 11:45:45 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aileron Therapeutics Inc (NASDAQ: ALRN ) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cerus Corporation (NASDAQ: CERS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) Emergent Biosolutions Inc (NYSE: EBS ) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) Imara Inc (NASDAQ: IMRA ) Immunovant Inc (NASDAQ: IMVT ) Inari Medical Inc (NASDAQ: NARI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MEI Pharma Inc (NASDAQ: MEIP ) Novo Nordisk A/S (NYSE: NVO ) Protara Therapeutics Inc (NASDAQ: TARA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) Ocugen Inc (NASDAQ: OCGN ) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs.
   MEI Pharma to Present at the Jefferies Virtual Healthcare Conference  2020/05/27 12:00:00 PR Newswire
SAN DIEGO, May 27, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overview and…
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry  2020/05/21 12:36:00 Zacks Investment Research
MEI Pharma (MEIP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?  2020/05/15 13:09:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in MEI Pharma, Inc. (MEIP).

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 MEIファ―マ MEIP MEI Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)